Guardant Health and Zephyr AI have partnered to advance the discovery of novel cancer biomarkers, as more precise tumour treatment becomes ever more principal in healthcare.
Under the collaboration, Guardant’s multimodal molecular DNA repository will be combined with Zephyr’s artificial intelligence and machine learning (AI/ML) capabilities to drive insights into cancer biomarkers in areas such as targeted therapy selection and drug response monitoring.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the companies, pairing Guardant multimodal real-world data and precision oncology insights with Zephyr’s proprietary AI technologies will accelerate research and development for biopharma partners.
They added that the partnership will generate predictions of targeted cancer therapy response validated by real-world data, integrating biologic interpretability features that result in actionable scientific intelligence.
Guardant’s co-CEO Helmy Eltoukhy stated that the combination of the US-based company’s molecular data with Zephyr AI platform will mark a step toward in realising the full potential of precision oncology to accelerate drug development and deliver better patient outcomes.
Zephyr focuses on curating large datasets that it combines with AI algorithms to build tools and products for the healthcare industry. Backed by Eli Lilly, in March 2024 the startup closed a $111m Series A funding round to further develop its platform.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataZephyr’s CEO Allen Chao commented: “This collaboration represents the convergence of unmatched real-world data, leading-edge diagnostics and cutting-edge machine learning to enable more precise, scalable, and impactful oncology solutions.
“By working together, Guardant Health and Zephyr AI can supercharge discovery and development needed to transform cancer treatment and deliver on the promise of personalised medicines for cancer patients.”
Guardant is perhaps best known for its Shield in vitro diagnostic (IVD) for colorectal cancer. The test gained US Food and Drug Administration (FDA) clearance in July 2024 after weathering an FDA Advisory Committee (AdCom) meeting in June over concerns surrounding the test’s low sensitivity in identifying early cases of colon cancer. The AdCom ultimately voted 7-2 in favour of approving the test, determining that its potential benefits outweighed its risks.
With application across myriad healthcare sectors, GlobalData analysis forecasts that AI’s deployment in the space will reach a $19bn valuation by 2027.
